AZITHROMYCIN'S FUNCTION AMONG PATIENTS
Keywords:
Acute generalized exanthematous pustulosis (AGEP), melena, jaundice, flatus.Abstract
The total rate of adverse events to Azithromycin is 0.7%. Only diarrhea, nausea, and abdominal pain were experienced by more than 1% of individuals. Palpitation, angina, dyspepsia, flatus, vomiting, melena, jaundice, vaginal candidiasis, vaginitis, nephritis, dizziness, headache, vertigo, somnolence, and weariness were also recorded in adult clinical studies. After low-dose use, Azithromycin has also been linked to angioedema and photosensitivity, intrahepatic cholestasis, hypersensitivity syndrome, toxic pustuloderma, and irreversible deafness. When given to patients with infectious mononucleosis, it can cause a maculopapular eruption. It is also capable of causing contact dermatitis. The study included 87 patients at the Clinical Hospital in Tetovo, as well as some children in the Pediatric department. The tolerability of Azithromycin oral suspension, 10 mg/kg once daily for 3 days, was evaluated in children at the Pediatric department of a clinical hospital in Tetovo. The incidence of treatment-related adverse events was considerably lower in the 87 individuals who took Azithromycin, whereas withdrawal rates were comparable. With Azithromycin, there were much fewer gastrointestinal problems and their duration was significantly shorter.
References
Arabi, Y. M., Deeb, A. M., Al-Hameed, F., Mandourah, Y., Almekhlafi, G. A., Sindi, A. A., ... & Saudi Critical Care Trials group. (2019). Macrolides in critically ill patients with Middle East Respiratory Syndrome. International Journal of Infectious Diseases, 81, 184-190. https://doi.org/10.1016/j.ijid.2019.01.041
Pinto, L. A., Pitrez, P. M., Luisi, F., de Mello, P. P., Gerhardt, M., Ferlini, R., ... & Marostica, P. J. (2012). Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial. The Journal of pediatrics, 161(6), 1104-1108. https://doi.org/10.1016/j.jpeds.2012.05.053
Echeverría-Esnal, D., Martin-Ontiyuelo, C., Navarrete-Rouco, M. E., De-Antonio Cuscó, M., Ferrández, O., Horcajada, J. P., & Grau, S. (2021). Azithromycin in the treatment of COVID-19: a review. Expert review of anti-infective therapy, 19(2), 147-163. https://doi.org/10.1080/14787210.2020.1813024
Vos, R., Vanaudenaerde, B. M., Verleden, S. E., De Vleeschauwer, S. I., Willems-Widyastuti, A., Van Raemdonck, D. E., ... & Verleden, G. M. (2011). A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. European Respiratory Journal, 37(1), 164-172. https://doi.org/10.1183/09031936.00068310
Goldman, R. C., Fesik, S. W., & Doran, C. C. (1990). Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. Antimicrobial agents and chemotherapy, 34(3), 426-431. ttps://doi.org/10.1128/aac.34.3.426
Jelić, D., & Antolović, R. (2016). From erythromycin to azithromycin and new potential ribosome-binding antimicrobials. Antibiotics, 5(3), 29. https://doi.org/10.3390/antibiotics5030029
Neu, H. C. (1991). Clinical microbiology of azithromycin. The American journal of medicine, 91(3), S12-S18. https://doi.org/10.1016/0002-9343(91)90395-E
Sidhu, A. B. S., Sun, Q., Nkrumah, L. J., Dunne, M. W., Sacchettini, J. C., & Fidock, D. A. (2007). In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. Journal of Biological Chemistry, 282(4), 2494-2504. https://doi.org/10.1074/jbc.M608615200
Biddau, M., & Sheiner, L. (2019). Targeting the apicoplast in malaria. Biochemical Society Transactions, 47(4), 973-983. https://doi.org/10.1042/BST20170563
Verleden, G. M., Vanaudenaerde, B. M., Dupont, L. J., & Van Raemdonck, D. E. (2006). Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. American journal of respiratory and critical care medicine, 174(5), 566-570. https://doi.org/10.1164/rccm.200601-071OC
Menzel, M., Akbarshahi, H., Bjermer, L., & Uller, L. (2016). Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Scientific reports, 6(1), 28698. https://doi.org/10.1038/srep28698
Drew, R. H., & Gallis, H. A. (1992). Azithromycin—spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 12(3), 161-173. https://doi.org/10.1002/j.1875-9114.1992.tb04504.x
Höffler, D., Paeske, B. & Koeppe, P. Pharmacokinetics of azithromycin in normal and impaired renal function. Infection 23, 356–361 (1995). https://doi.org/10.1007/BF01713565
Ioannidis, J. P., Contopoulos-Ioannidis, D. G., Chew, P., & Lau, J. (2001). Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. Journal of Antimicrobial Chemotherapy, 48(5), 677-689. https://doi.org/10.1093/jac/48.5.677
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012). Azithromycin and the risk of cardiovascular death. New England Journal of Medicine, 366(20), 1881-1890. https://doi.org/10.1056/NEJMoa1003833
Svanström, H., Pasternak, B., & Hviid, A. (2013). Use of azithromycin and death from cardiovascular causes. New England Journal of Medicine, 368(18), 1704-1712. https://doi.org/10.1056/NEJMoa1300799
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
